MedPage Today on MSN

Navigating Second-Line Endocrine Options in Breast Cancer

The second-line endocrine therapy landscape in hormone receptor (HR)-positive, HER2-negative advanced breast cancer is becoming increasingly complex, with decisions now shaped by ESR1 and PIK3CA ...

SIGGRAPH Asia 2025 Unveils This Year's Winning Animated Stories at Its Computer Animation Festival in Hong Kong

Animation's future will be on full display as the SIGGRAPH Asia 2025 Computer Animation Festival (CAF), organized by Koelnmesse Pte Ltd, announces this year's winners – works that redefine the ...

Should You Buy Netflix Stock Today After Its 10-for-1 Split?

Netflix (NFLX) began trading Monday, Nov. 17 on a split adjusted basis, after enacting a 10-for-1 split that makes its shares ...
Nature

Endocrine cancer articles from across Nature Portfolio

FDA approval of the selective HIF2α inhibitor belzutifan for advanced phaeochromocytoma and paraganglioma (PPGL) is an important milestone in precision oncology. This achievement underscores the power ...